Table 1.
Baseline characteristics of the total study population.
| Characteristics | n = 1,114 |
|---|---|
| Clinical data | |
| Age, year | 55.8 ± 7.5 |
| Male, n (%) | 921 (82.7) |
| Systolic blood pressure, mmHg | 123.3 ± 13.7 |
| Diastolic blood pressure, mmHg | 78.2 ± 10.1 |
| BMI, kg/m2 | 25.4 ± 3.0 |
| Obesity, n (%) | 598 (53.7) |
| Hypertension, n (%) | 579 (52.0) |
| Hyperlipidemia, n (%) | 494 (44.3) |
| Current smoking, n (%) | 338 (30.8) |
| Family history of CAD, n (%) | 137 (12.3) |
| Framingham risk score | 12.0 ± 6.0 |
| Framingham risk stratification, n (%) | |
| Low | 483 (43.4) |
| Intermediate | 514 (46.1) |
| High | 117 (10.5) |
| Total cholesterol, mg/dL | 186.6 ± 38.6 |
| Triglyceride, mg/dL | 159.3 ± 115.7 |
| HDL-C, mg/dL | 50.3 ± 12.3 |
| LDL-C, mg/dL | 112.8 ± 32.9 |
| High triglyceride, n (%) | 446 (40.0) |
| High HDL-C, n (%) | 862 (77.4) |
| High LDL-C, n (%) | 713 (64.0) |
| Fasting glucose, mg/dL | 134.0 ± 32.5 |
| HbA1C, % | 6.8 ± 1.2 |
| Creatinine, mg/dL | 0.9 ± 0.2 |
| Anti-hypertensive treatment, n (%) | 467 (41.9) |
| Anti-hyperlipidemic treatment, n (%) | 291 (26.1) |
| Anti-diabetic treatment, n (%) | 576 (51.7) |
| OGC, n (%) | 746 (67.0) |
| CCTA data | |
| CACS | 78.0 ± 194.6 |
| Any plaque, n (%) | 644 (57.8) |
| Calcified plaque, n (%) | 468 (42.0) |
| Non-calcified plaque, n (%) | 277 (24.9) |
| Mixed plaque, n (%) | 178 (16.0) |
| Obstructive plaque, n (%) | 158 (14.2) |
Values are presented as means ± standard deviation or as numbers (%).
BMI body mass index, CACS coronary artery calcium score, CAD coronary artery disease, CCTA coronary computed tomographic angiography, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, OGC optimal glycemic control.